New science-based endpoints to accelerate oncology drug development

European Journal of Cancer

Volumn 41, Issue 4, 2005, Pages 491-501

  Kelloff, Gary J ^a   Sigman, Caroline C ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CCS Associates   (United States)

Author keywords

Biomarker; Drug development; Functional imaging; Genomics; Molecular imaging; Oncology; Proteomics; Surrogate endpoint

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; BORTEZOMIB; CELECOXIB; GEFITINIB; IMATINIB; LETROZOLE; TAMOXIFEN; TRASTUZUMAB;

BIOASSAY; BREAST CANCER; CANCELLOUS BONE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PREVENTION; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; COMPUTER ANALYSIS; CONFOCAL MICROSCOPY; COST EFFECTIVENESS ANALYSIS; DISEASE MARKER; DRUG APPROVAL; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG SAFETY; DRUG TARGETING; ENDOSCOPY; FLUORESCENCE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; GENOMICS; HUMAN; IMAGE ANALYSIS; IMAGING SYSTEM; LUNG CANCER; MULTIPLE MYELOMA; NANOTECHNOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; REVIEW; TREATMENT OUTCOME;

EID: 14344251403     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.12.006     Document Type: Article

References (87)

1. J. Albanell, and J. Baselga Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer Drugs Tod (Barc) 35 12 1999 931 946
2. M.H. Cohen, J.R. Johnson, and N. Li Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer Clin Cancer Res 8 3 2002 665 669
3. I.R. Radford Imatinib. Novartis Curr Opin Investig Drugs 3 3 2002 492 499
4. R.C. Kane, P.F. Bross, and A.T. Farrell Velcade: US FDA approval for the treatment of multiple myeloma progressing on prior therapy Oncologist 8 6 2003 508 513
5. M.H. Cohen, G.A. Williams, and R. Sridhara FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets Oncologist 8 4 2003 303 306
6. D. Cunningham, Y. Humblet, and S. Siena Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 4 2004 337 345
7. C. Erlichman, and D.J. Sargent New treatment options for colorectal cancer N Engl J Med 351 4 2004 391 392
8. J. Gilbert Rebuilding big PhRMA's business model In Vivo November 2003 73 80
9. L.J. Lesko, and J. Woodcock Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective Nat Rev Drug Discov 3 9 2004 763 769
10. Tufts CDSS quantifies savings from boosting new drug R&D efficiency. Tufts CSDD Impact Report 2002, 1-4
11. J.M. Reichert Trends in development and approval times for new therapeutics in the United States Nat Rev Drug Discov 2 9 2003 695 702
12. M.L. Salgaller Technology evaluation: bevacizumab, Genentech/Roche Curr Opin Mol Ther 5 6 2003 657 667
13. B. Gatto Monoclonal antibodies in cancer therapy Curr Med Chem Anti-Canc Agents 4 5 2004 411 414
14. R.E. Smith, R.C. Renaud, and E. Hoffman Colorectal cancer market Nat Rev Drug Discov 3 6 2004 471 472
15. B. Fisher, J.P. Costantino, and D.L. Wickerham Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 90 18 1998 1371 1388
16. G. Steinbach, P.M. Lynch, and R.K. Phillips The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis N Engl J Med 342 26 2000 1946 1952
17. R.K. Phillips, M.H. Wallace, and P.M. Lynch A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase2 inhibitor, on duodenal polyposis in familial adenomatous polyposis Gut 50 6 2002 857 860
18. J.A. O'Shaughnessy, G.J. Kelloff, and G.B. Gordon Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development Clin Cancer Res 8 2 2002 314 346
19. P. Rolan, A.J. Atkinson Jr., and L.J. Lesko Use of biomarkers from drug discovery through clinical practice: report of the ninth European Federation of pharmaceutical sciences conference on optimizing drug development Clin Pharmacol Ther 73 4 2003 284 291
20. G.J. Kelloff, R.C. Bast Jr., and D.S. Coffey Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue Clin Cancer Res 10 11 2004 3881 3884
21. G.J. Kelloff, R.L. Schilsky, and D.S. Alberts Colorectal adenomas: a prototype for the use of surrogate endpoints in the development of cancer prevention drugs Clin Cancer Res 10 11 2004 3908 3918
22. G.J. Rustin, R.C. Bast Jr., and G.J. Kelloff Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer Clin Cancer Res 10 11 2004 3919 3926
23. G.J. Kelloff, D.S. Coffey, and B.A. Chabner Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer Clin Cancer Res 10 11 2004 3927 3933
24. J.W. Park, R.S. Kerbel, and G.J. Kelloff Rationale for biomarkers and surrogate endpoints in mechanism-driven oncology Clin Cancer Res 10 11 2004 3885 3896
25. G.F. Vande Woude, G.J. Kelloff, and R.W. Ruddon Reanalysis of cancer drugs: old drugs, new tricks Clin Cancer Res 10 11 2004 3897 3907
26. A.C. von Eschenbach A vision for the National Cancer Program in the United States Nat Rev Cancer 4 8 2004 820 828
27. G.J. Kelloff, J.A. O'Shaughnessy, and G.B. Gordon Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers Cancer Epidemiol Biomarkers Prev 12 7 2003 593 596
28. R.J. Temple A regulatory authority's opinion about surrogate endpoints W.S. Nimmo G.T. Tucker Clinical measurement in drug evaluation 1995 John Wiley and Sons, Inc. New York 1 2
29. J.R. Johnson, G. Williams, and R. Pazdur End points and United States food and drug administration approval of oncology drugs J Clin Oncol 21 7 2003 1404 1411
30. A.B. Miller, B. Hoogstraten, and M. Staquet Reporting results of cancer treatment Cancer 47 1981 207 214
31. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 2000 205 216
32. R.L. Schilsky, and S.E. Taube Tumor markers as clinical cancer tests-are we there yet? Semin Oncol 29 3 2002 211 212
33. M.E. Hammond, and S.E. Taube Issues and barriers to development of clinically useful tumor markers: a development pathway proposal Semin Oncol 29 3 2002 213 221
34. S. Gutman Regulatory issues in tumor marker development Semin Oncol 29 3 2002 294 300
35. G.J. Rustin, M. Marples, and A.E. Nelstrop Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels J Clin Oncol 19 20 2001 4054 4057
36. G.J. Rustin Use of CA-125 to assess response to new agents in ovarian cancer trials J Clin Oncol 21 Suppl. 10 2003 187 193
37. A.V. D'Amico, K. Cote, and M. Loffredo Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer J Clin Oncol 20 23 2002 4567 4573
38. A.V. D'Amico, J.W. Moul, and P.R. Carroll Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy J Natl Cancer Inst 95 18 2003 1376 1383
39. B.S. Hulka, and T. Wilcosky Biological markers in epidemiologic research Arch Environ Health 43 2 1988 83 89
40. E.R. Fearon Human cancer syndromes: clues to the origin and nature of cancer Science 278 5340 1997 1043 1050
41. R. Frank, and R. Hargreaves Clinical biomarkers in drug discovery and development Nat Rev Drug Discov 2 7 2003 566 580
42. G.J. Kelloff, C.W. Boone, and J.A. Crowell Risk biomarkers and current strategies for cancer chemoprevention J Cell Biochem Suppl 25 1996 1 14
43. G.J. Kelloff Perspectives on cancer chemoprevention research and drug development Adv Cancer Res 78 2000 199 334
44. M.H. Gail, and M.H. Greene Gail model and breast cancer Lancet 355 9208 2000 1017
45. J. Baselga Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials Oncology 61 Suppl. 2 2001 14 21
46. P. Birner, G. Oberhuber, and J. Stani Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer Clin Cancer Res 7 6 2001 1669 1675
47. L.M. Staudt Molecular diagnosis of the hematologic cancers N Engl J Med 348 18 2003 1777 1785
48. L.J. Lesko Jr., and A.J. Atkinson Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies Ann Rev Pharmacol Toxicol 41 2001 347 366
49. G.J. Kelloff, C.C. Sigman, and K.M. Johnson Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer Cancer Epidemiol Biomarkers Prev 9 2 2000 127 137
50. A.F. LoBuglio, J. Pluda, and P. Ivy Biomarkers in cancer therapeutics G.J. Downing Biomarkers and surrogate endpoints: clinical research and applications 2000 Elsevier Science BV Amsterdam 233 254
51. M.S. Pepe, R. Etzioni, and Z. Feng Phases of biomarker development for early detection of cancer J Natl Cancer Inst 93 14 2001 1054 1061
52. D.F. Ransohoff Rules of evidence for cancer molecular-marker discovery and validation Nat Rev Cancer 4 4 2004 309 314
53. R.L. Prentice Surrogate endpoints in clinical trials: definition and operational criteria Stat Med 8 4 1989 431 440
54. T.R. Fleming, R.L. Prentice, and M.S. Pepe Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research Stat Med 13 9 1994 955 968
55. G.J. Kelloff, C.C. Sigman, and E.T. Hawk Surrogate end-point biomarkers in chemopreventive drug development IARC Sci Publ 154 2001 13 26
56. V.G. De Gruttola, P. Clax, and D.L. DeMets Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop Control Clin Trials 22 5 2001 485 502
57. P. Rolan The contribution of clinical pharmacology surrogates and models to drug development -a critical appraisal Br J Clin Pharmacol 44 3 1997 219 225
58. B.N. Swanson Delivery of high-quality biomarker assays Dis Markers 18 2 2002 47 56
59. P.M. Bossuyt, J.B. Reitsma, and D.E. Bruns The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration Ann Int Med 138 1 2003 W1-12
60. L. Kopelovich, D.E. Henson, and A.F. Gazdar Surrogate anatomic/functional sites for evaluating cancer risk: an extension of the field effect Clin Cancer Res 5 12 1999 3899 3905
61. E. Racila, D. Euhus, and A.J. Weiss Detection and characterization of carcinoma cells in the blood Proc Natl Acad Sci USA 95 8 1998 4589 4594
62. J.G. Moreno, S.M. O'Hara, and S. Gross Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status Urology 58 3 2001 386 392
63. S. Monestiroli, P. Mancuso, and A. Burlini Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma Cancer Res 61 11 2001 4341 4344
64. P. Mancuso, A. Calleri, and C. Cassi Circulating endothelial cells as a novel marker of angiogenesis Adv Exp Med Biol 522 2003 83 97
65. P.E. Lonning, T. Sorlie, and C.M. Perou Microarrays in primary breast cancer - lessons from chemotherapy studies Endocr Relat Cancer 8 3 2001 259 263
66. M. van de Rijn, C.M. Perou, and R. Tibshirani Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome Am J Pathol 161 6 2002 1991 1996
67. M.J. van de Vijver, Y.D. He, and L.J. van't Veer A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 347 25 2002 1999 2009
68. S. Ramaswamy, and C.M. Perou DNA microarrays in breast cancer: the promise of personalised medicine Lancet 361 9369 2003 1576 1577
69. C.P. Paweletz, L.A. Liotta, and E.F. Petricoin III New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics Urology 57 4 Suppl. 1 2001 160 163
70. V.E. Bichsel, L.A. Liotta, and E.F. Petricoin III Cancer proteomics: from biomarker discovery to signal pathway profiling Cancer J 7 1 2001 69 78
71. J.D. Wulfkuhle, K.C. McLean, and C.P. Paweletz New approaches to proteomic analysis of breast cancer Proteomics 1 10 2001 1205 1215
72. M.B. Jones, H. Krutzsch, and H. Shu Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer Proteomics 2 1 2002 76 84
73. C.M. Michener, A.M. Ardekani, and E.F. Petricoin III Genomics and proteomics: application of novel technology to early detection and prevention of cancer Cancer Detect Prev 26 4 2002 249 255
74. E.F. Petricoin, A.M. Ardekani, and B.A. Hitt Use of proteomic patterns in serum to identify ovarian cancer Lancet 359 9306 2002 572 577
75. E.F. Petricoin III, J.L. Hackett, and L.J. Lesko Medical applications of microarray technologies: a regulatory science perspective Nat Genet Suppl. 32 2002 474 479
76. E.F. Petricoin III, D.K. Ornstein, and C.P. Paweletz Serum proteomic patterns for detection of prostate cancer J Natl Cancer Inst 94 20 2002 1576 1578
77. E.F. Petricoin, K.C. Zoon, and E.C. Kohn Clinical proteomics: translating benchside promise into bedside reality Nat Rev Drug Discov 1 9 2002 683 695
78. R.L. Grubb, V.S. Calvert, and J.D. Wulkuhle Signal pathway profiling of prostate cancer using reverse phase protein arrays Proteomics 3 11 2003 2142 2146
79. A.L. Clark, A.M. Gillenwater, and T.G. Collier Confocal microscopy for real-time detection of oral cavity neoplasia Clin Cancer Res 9 13 2003 4714 4721
80. J.M. Lewin, C.J. D'Orsi, and R.E. Hendrick Digital mammography Radiol Clin North Am 42 5 2004 871 884 vi
81. T. Takayama, S. Katsuki, and Y. Takahashi Aberrant crypt foci of the colon as precursors of adenoma and cancer N Engl J Med 339 18 1998 1277 1284
82. W.A. Qureshi Current and future applications of the capsule camera Nat Rev Drug Discov 3 5 2004 447 450
83. R. Weissleder, C.H. Tung, and U. Mahmood In vivo imaging of tumors with protease-activated near-infrared fluorescent probes Nat Biotechnol 17 4 1999 375 378
84. A. Alavi, J.W. Kung, and H. Zhuang Implications of PET based molecular imaging on the current and future practice of medicine Semin Nucl Med 34 1 2004 56 69
85. H. Otsuka, M. Graham, and A. Kubo Clinical utility of FDG PET J Med Invest 51 1-2 2004 14 19
86. E.M. Rohren, T.G. Turkington, and R.E. Coleman Clinical applications of PET in oncology Radiology 231 2 2004 305 332
87. R. Dagher, J. Johnson, and G. Williams Accelerated approval of oncology products: a decade of experience J Natl Cancer Inst 96 20 2004 1500 1509